Provider Knowledge, Use, and Barriers to the Uptake of PEP and PrEP

Amanda D. Castel, MD, MPH

George Washington University School of Public Health and Health Services



WASHINGTON, DC





Background

- In 2005, CDC recommended use of non-occupational post exposure prophylaxis (nPEP) for HIV prevention among individuals at high-risk
- nPEP as a prevention strategy has not been widely implemented in the District of Columbia (DC)
- In 2011, CDC issued guidance on use of pre-exposure prophylaxis
 (PrEP) among MSM and heterosexuals at high-risk for HIV
- DC Department of health planning to
 - Conduct a demonstration project to increase utilization of nPEP
 - Preparing for an open-label PrEP demonstration project among
 Medicaid recipients

Objectives and Methods

- Objectives: to determine knowledge, use, and barriers to nPEP and PrEP uptake among healthcare providers in DC
- Surveyed all licensed infectious disease (ID) and American
 Academy of HIV Medicine Certified HIV providers in DC between
 March and August 2012
- Assessed provider knowledge, attitudes, use, and perceived barriers to using nPEP and PrEP
- Calculated descriptive statistics and performed bivariate analyses to identify potential differences in knowledge and use by provider type


Results: Provider and Practice Characteristics (N=58)

Characteristics	N (%)		
Age group: ≥50 yrs old	28(48.3)		
White non-Hispanic	39 (67.2)		
Male	29 (50)		
Infectious disease physician	25 (43.1)		
>20 years in practice	24 (41.4)		
Patients seen in 1 month at practice: >200	26 (44.8)		
HIV patients seen in 3 months: >20	49 (84.5)		
HIV patients seen by respondent in 3 months:>20	44 (75.9)		

Results: nPEP and PrEP Provider Survey


	nPEP		PrEP	
	N	%	N	%
Aware of CDC guidelines				
Yes	47	81.0	34	58.6
No	1	1.7	14	24.1
Protocols in place at practice				
Yes	18	31.0	7	12.1
No	31	53.4	41	70.7
How often encountered patients requesting nPEP/PrEP in past 6 months				
Often (at least once per week)	4	6.9	3	5.2
Occasionally (a few times a month)	13	22.4	4	6.9
Rarely (less than once a month)	18	31.0	19	32.8
Never	22	37.9	29	50.0
Missing	1	1.7	3	5.2
Ever prescribed nPEP/PrEP				
Yes	34	58.6	13	22.4
No	23	39.7	42	72.4
Missing	1	1.7	3	5.2

Patient Factors Influencing Likelihood of Prescribing nPEP/PrEP



*No significant differences observed by provider type

Acceptability of Prescribing nPEP/PrEP




*No significant differences observed by provider type

Provider Concerns with Prescribing nPEP and PrEP

Greatest Concerns with Prescribing nPEP

Would lead to increased 3%_ 2% risk behavior ■ Patient noncompliance 12% with therapy 19% Development of viral 10% resistance to antiretrovirals Adverse effects of therapy 16% 26% Cost of therapy 12% ■ No concerns about prescribing nPEP

Greatest Concerns with Prescribing PrEP



^{*}No significant differences observed by provider type

Conclusions

- HIV Providers in DC are familiar with and currently prescribing nPEP and PrEP to select high-risk populations
- Similar barriers to providing nPEP and implementation of PrEP were identified including:
 - Antiretroviral resistance
 - Cost reimbursement
- To maximize increase and uptake of both prevention approaches, the DC Department of Health should focus on:
 - Increasing patient awareness of nPEP and PrEP through education and social marketing
 - Collaborating with health insurers to ensure coverage for medications and administrative costs associated with delivery of nPEP and PrEP

Acknowledgments

GWU

- Morgane Bennett
- Kristen Camuso
- James Peterson
- Jennifer Skillicorn
- John Wedeles
- Sarah Willis

DC DOH HAHSTA

- Michael Kharfen
- Tiffany West

Funding Support: DC Developmental Center for AIDS Research ECHPP Supplemental Award





Questions

Email: acastel@gwu.edu